GLP-1 Receptor Agonist [EPC]

157857 reported adverse events

Drugs of this class: LIRAGLUTIDE SEMAGLUTIDE DULAGLUTIDE EXENATIDE (INSULIN DEGLUDEC AND LIRAGLUTIDE) INSULIN GLARGINE AND LIXISENATIDE LIXISENATIDE ORAL SEMAGLUTIDE

These side effects are most commonly reported by patients taking drugs of the GLP-1 Receptor Agonist [EPC] class:

# Side effect Count
0 BLOOD GLUCOSE INCREASED 26307
1 NAUSEA 26007
2 WEIGHT DECREASED 17779
3 VOMITING 10928
4 INJECTION SITE PAIN 10654
5 DECREASED APPETITE 9924
6 DIARRHOEA 9527
7 BLOOD GLUCOSE DECREASED 8096
8 INJECTION SITE HAEMORRHAGE 7324
9 PANCREATITIS 5659
See all common reactions for GLP-1 Receptor Agonist [EPC]

Drugs of the GLP-1 Receptor Agonist [EPC] class are most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 EARLY SATIETY 673 0.5072
1 MEDULLARY THYROID CANCER 68 0.4024
2 DRUG DELIVERY SYSTEM ISSUE 175 0.3708
3 INJECTION SITE NODULE 2877 0.3524
4 GLYCOSYLATED HAEMOGLOBIN ABNORMAL 99 0.3103
5 INTENTIONAL DEVICE MISUSE 941 0.3073
6 ACCIDENTAL UNDERDOSE 1129 0.2916
7 INJECTION SITE EXTRAVASATION 2596 0.2677
8 GLYCOSYLATED HAEMOGLOBIN DECREASED 217 0.2653
9 PANCREATIC CARCINOMA METASTATIC 575 0.2612
See all enriched reactions for GLP-1 Receptor Agonist [EPC]